The emergence of the need for safety and efficacy of a drug subjected to individual patients has made companion diagnostics one of the most sought after topics in the field of In-Vitro Diagnostics. The surge of investment in companion diagnostics has brought forward issues regarding regulations and their intricacies and boosted new trends in immuno-oncology, immuno-therapies, data interpretation and unconventional design of clinical trials.
The 4th Annual Biomarker and Companion Diagnostics Conference scheduled to be held on 6th - 7th October 2022 in London, UK would address the gaps between early-stage biomarker development and the commercialization stage of biomarkers.
This conference would also highlight case studies on leveraging emerging technologies in Digital Biomarkers, Precision Medicine and Big Data. Regarding the commercialization of biomarkers, leading industry and academic experts would share their case studies focusing on advancements in the companion diagnostics area. The keynote presentations would also help the attendees understand the issues related to the clinical translation of biomarkers.
Research Scientist, Imperial College London
Chief Scientific Officer, Proteome Sciences PLC
Vice President, Translational Biology, Crescendo Biologics
Founder and Head of R&D, MiNA Therapeutics
Senior Scientist, Orchard Therapeutics
Product Manager, HAWK Biosystems
Professor of Molecular Oncology (Barts Cancer Institute), Queen Mary University of London (QMUL)
Lecturer, Machine Learning, University of Surrey
CEO, Monument Therapeutics
Researcher, Imperial College London
Principal Clinical Pharmacologist, SOBI
Assistant Professor, Teesside University
Vice President, MiNA Therapeutics
Cancer Bioinformatician, King’s College London
Assistant Professor, Department of Biomolecular Health Sciences, Utrecht University, The Netherlands
Co-founder, MicroOmiX Tech
Metabolomics Application Specialist, Metabolon
ISH Venues, 1 Park Cres, London W1B 1SH, United Kingdom